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Abstract
Background: The rate of urinary tract infections (UTIs) due to extended-spectrum β-lactamase (ESBL)-producing
bacterial strains requiring carbapenem therapy has been increasing in children. This study was conducted to evaluate the
effect of non-carbapenem antibiotic therapy on childhood UTIs caused by ESBL-producing Escherichia coli or Klebsiella
pneumoniae.
Methods: Medical records of children diagnosed with febrile UTIs due to E. coli or K. pneumoniae between 2010 and
2014 were retrospectively reviewed. The enrolled children were divided into two groups: the ESBL group and the
non-ESBL group. Clinical characteristics and therapeutic responses were compared between the two groups.
Results: A total of 211 episodes of UTI (204 caused by E. coli; seven caused by K. pneumoniae) were identified in 205
children. Twenty-two (10.4 %) episodes were categorized into the ESBL group. There was no significant difference in the
type of antibiotic administered between the two groups. No carbapenems were administered; however, aminoglycosides
were administered for 79.1 % of the total episodes. Although empirical antibiotics were appropriate for more episodes in
the non-ESBL group compared with the ESBL group (100.0 % vs. 90.9 %, p = 0.011), there were no significant differences
in the frequency of defervescence, bacterial eradication from the urine, acute pyelonephritis and vesicoureteral reflux or
fever duration between the two groups.
Conclusions: Non-carbapenem antibiotics showed favourable therapeutic effects on childhood UTIs caused by
ESBL-producing strains. Aminoglycosides can be an alternative to carbapenems in such cases.
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Background
Urinary tract infections (UTIs) are one of the most
common bacterial infections in children, and are
most frequently caused by Enterobacteriaceae, includ-
ing Escherichia coli and Klebsiella pneumoniae [1, 2].
Third-generation cephalosporins have been widely
used for the treatment of community-acquired UTIs;
however, the rate of UTIs caused by extended-
spectrum β-lactamase (ESBL)-producing E. coli or K.
pneumoniae, which are resistant to cephalosporins, has
been increasing in adults as well as children [3–6]. In
addition, UTIs due to ESBL-producing strains may cause
prolonged hospital stay and an increase in medical costs
[2, 5, 6]. Although carbapenems are recommended for
treating infections caused by ESBL-producing strains [7, 8],
their use should be restricted given the concerns regarding
increasing resistance [9, 10]. Fortunately, non-carbapenem
antibiotic therapy has shown favourable therapeutic effects
on UTIs due to ESBL-producing strains in adults; however,
studies in children are scarce [11, 12].
This retrospective study compared clinical and micro-
biological responses to non-carbapenem antibiotic therapy
between febrile UTIs caused by ESBL-producing E. coli or
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K. pneumoniae and febrile UTIs caused by non-ESBL-
producing strains in healthy children. In addition, the
efficacy of non-carbapenem antibiotics administered to
children with UTIs caused by ESBL-producing strains
was also evaluated.
Methods
Patients and study design
Medical records for children (<18 years of age) diag-
nosed with a febrile UTI caused by E. coli or K. pneu-
moniae in the inpatient and outpatient clinics of the
Department of Pediatrics at Seoul St. Mary’s Hospital,
Seoul, Republic of Korea, between January 2010 and
December 2014 were retrospectively reviewed. To avoid
the inclusion of hospital-acquired UTIs, data were ex-
cluded if urine cultures were performed 48 h or more after
admission to hospital. Data for immunocompromised chil-
dren with underlying haematological/oncological diseases
as well as data for children with underlying chronic neuro-
logical disorders, haemodynamically unstable congenital
heart diseases, underlying functional and anatomical uro-
logical disorders, indwelling urinary catheters, or other
febrile illnesses with accompanying pyuria (e.g. polymerase
chain reaction-confirmed respiratory viral infection or
Kawasaki disease) were also excluded. A UTI was diag-
nosed in febrile children when the following criteria were
met: 1) positive results on a urine dipstick test (leukocyte
esterase or nitrite) or a white blood cell count > 10/high
power field on urinary flow cytometry analysis, 2) identifi-
cation of a single pathogen with > 100,000 colony forming
units/mL in a urine culture. Urine samples were collected
from non-toilet-trained children by applying a sterile urine
bag over the perineum after skin disinfection, and clean,
voided midstream urine was collected from toilet-trained
children. The data for the enrolled children were divided
into ESBL and non-ESBL groups based on the ESBL posi-
tivity of the identified urinary pathogen. The clinical char-
acteristics of the two groups were then compared. This
study was approved by the Institutional Review Board of
Seoul St. Mary’s Hospital (Approval No.: KC15RISI0119).
Informed consent was waived for this study.
Comparison of demographic and clinical characteristics
Age, sex, identified urinary pathogens, previous history
of UTIs, and fever duration (before and after antibiotic
therapy) were compared between the two groups.
Acute pyelonephritis (APN) was diagnosed according
to 99mtechnetium dimercaptosuccinic acid (DMSA)
scan results. Vesicoureteral reflux (VUR) was diagnosed
according to voiding cystourethrography (VCUG) results.
The rates of APN and VUR were compared between the
two groups. Almost all pregnant women in the Republic
of Korea receive regular antepartum care and repeated
foetal ultrasonography, and therefore, clinicians in our
hospital focus on identifying APN rather than urogenital
structural anomalies in children diagnosed with UTIs.
DMSA scans, which are more sensitive in diagnosing
APN than renal ultrasonography, are performed for most
UTI episodes in our hospital for such a purpose.
Comparison of administered antibiotic therapy
Antibiotics that were initially administered to febrile
children before the identification of the urinary pathogen
and its antibiotic susceptibility were defined as empirical
antibiotics. To evaluate the therapeutic effect of the em-
pirical antibiotics, the type and appropriateness of the
antibiotics, duration of antibiotic therapy, and frequency
of defervescence and bacterial eradication from the urine
during empirical therapy were compared between the
two groups. Empirical antibiotic therapy was considered
appropriate if the identified uropathogen was susceptible
to at least one of the administered empirical antibiotics.
If the identified pathogen was non-susceptible to all of
the empirical antibiotics, the therapy was considered
inappropriate.
Comparison of antibiotic susceptibility rates
Urine cultures and the identification of urinary pathogens
were performed using the VITEK®2 automated system
(bioMérieux, Hazelwood, MO, USA). Antibiotic suscepti-
bility tests and the identification of ESBL were performed
using antibiotic susceptibility test cards (VITEK®2 auto-
mated system). In cases for which a cefotaxime suscepti-
bility test was not performed, ceftazidime susceptibility
results were applied to determine cefotaxime susceptibil-
ity, and cefotaxime or ceftazidime susceptibility results
were applied to determine susceptibilities to oral third-
generation cephalosporins (e.g. cefpodoxime, cefditoren,
and cefixime). Susceptibility to amoxicillin/clavulanate
and susceptibility to ampicillin/sulbactam were considered
identical. Susceptibility rates were compared between the
two groups.
Statistical analysis
A χ2 test was used to compare categorical variables while
numerical variables were compared using a Mann–
Whitney test. Statistical analyses were performed using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) and a
two tailed p < 0.05 was considered a significant result.
Results
During the study period, 211 episodes of febrile UTI
caused by E. coli or K. pneumoniae were diagnosed in
205 children. Eleven (5.2 %) of these episodes were
treated solely at the outpatient clinic. The median age of
the enrolled children was 5.0 months (interquartile
range, IQR: 3.0–7.0), and 128 (60.7 %) cases were boys.
Of the 211 episodes, 204 (96.7 %) were caused by E. coli
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while seven (3.3 %) were caused by K. pneumoniae
(Table 1). Twenty-two episodes were caused by ESBL-
producing strains, and 21 (95.5 %) of these were caused
by ESBL-producing E. coli (Table 1). Bacteraemia ac-
companied eight (3.8 %) of these episodes (seven in the
non-ESBL group and one in the ESBL group), although
none needed intensive care.
Comparison of demographic and clinical characteristics
Age, sex, and causative pathogens were compared between
the ESBL group (22 episodes, 10.4 %) and the non-ESBL
group (189 episodes, 89.6 %), and there were no significant
differences between the two groups (Table 1). A previous
history of UTIs was identified for 10 (4.7 %) of the epi-
sodes; however, the frequency of recurrence was not sig-
nificantly different between the two groups. The median
duration of fever at the beginning of antibiotic therapy was
2.0 days (IQR: 1.0-3.0) and was not significantly different
between the two groups (Table 1). APN was diagnosed in
144 (80.4 %) of the 179 episodes for which a DMSA scan
was performed and VUR was diagnosed in 22 (16.9 %) of
the 130 episodes for which VCUG was performed. The
APN and VUR frequencies were not significantly different
between the two groups (Table 1).
Comparison of clinical and microbiological responses to
antibiotic therapy
Cephalosporins or β-lactam/β-lactamase inhibitor com-
binations (BL/BLIs) were empirically administered in
addition to aminoglycosides in 167 (79.1 %) of the UTI
episodes. The type of empirical antibiotics was not
significantly different between the two groups (Table 2).
The empirical aminoglycosides were administered for a
median of 6.0 days (IQR: 4.5–7.0). The administration
of empirical aminoglycosides was discontinued during
hospitalisation for 16 (9.6 %) episodes based on the
antibiotic susceptibility results, and it was continued
during the entire period of hospitalisation in the
remaining episodes. Serum creatinine levels were re-
checked during aminoglycoside therapy in 81 episodes
(72 in the non-ESBL group, nine in the ESBL group),
but, none showed a rising serum creatinine level that
was more than twice that of baseline. Empirical antibi-
otics were appropriate in all episodes for the non-ESBL
group and 90.9 % for the ESBL group (p = 0.011,
Table 2). Fever disappeared in 92.3 % of UTI episodes
during empirical antibiotic therapy. There were no signifi-
cant differences between the two groups in frequency of
defervescence or duration of fever during empirical anti-
biotic therapy (Table 2). Urine cultures were repeated after
empirical antibiotic therapy (median 2 days, IQR: 2–3) for
all but 14 episodes (13 in the non-ESBL group and one in
the ESBL group). Urinary pathogens were eradicated for
99.0 % of the episodes for which repeated urine cultures
were performed. The rate of bacterial eradication during
empirical antibiotic therapy was not significantly different
between the two groups (Table 2). Among the 200 hospi-
talised cases, return visits to the outpatient clinic were
made for 193 (96.5 %) of the episodes within a median of
7.0 days (IQR: 5.0–8.0) after discharge from hospital, and
there were no re-emerging fever or urological symptoms
during the period.
Table 1 Characteristics of children with urinary tract infection caused by E. coli or K. pneumoniae
Factor Non-ESBL group ESBL group p-value
(n = 189) (n = 22)
Sex (male) 114 (60.3) 14 (63.6) 0.763
Age (months) 4.0 (3.0–7.0) 5.0 (4.0–6.5) 0.203
Pathogen 0.543
E. coli 183 (96.8) 21 (95.5)
K. pneumoniae 6 (3.2) 1 (4.5)
Methods of urine collection 0.119
Urine bag 174 (92.1) 18 (81.8)
Mid-stream urine 15 (7.9) 4 (18.2)
Previous history of urinary tract infection 9 (4.8) 1 (4.5) 1.000
Fever duration at the beginning of antibiotic therapy (days)a 2.0 (1.0-3.0) 2.0 (1.0-3.0) 0.923
Acute pyelonephritis on DMSA scanb 127 (80.4) 17 (81.0) 1.000
Vesicoureteral reflux on VCUGc 18 (15.9) 4 (23.5) 0.488
Data are median (interquartile range) or no. (%) of cases
ESBL extended-spectrum β-lactamase; DMSA 99mtechnetium dimercaptosuccinic acid; VCUG voiding cystoutrthrography
aThe accurate duration of fever at the beginning of antibiotic therapy was not determined in one child in the non-ESBL group, who was treated in the
outpatient clinic
bDMSA scan was performed in 179 children (158 in the non-ESBL group, 21 in the ESBL group)
cVCUG was performed in 130 children (113 in the non-ESBL group, 17 in the ESBL group)
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All episodes in the ESBL group were initially treated
with intravenous antibiotics, and oral antibiotics were
administered after discharge from hospital for 21
(95.5 %) episodes. Cefotaxime and amikacin were ad-
ministered for 13 (59.1 %) episodes, amoxicillin/clavula-
nate and amikacin for four (18.2 %), cefotaxime for
three (13.6 %), cefuroxime and amikacin for one (4.5 %),
and amoxicillin/clavulanate for one (4.5 %). However,
none of the ESBL group received carbapenem therapy.
Cefuroxime susceptibility testing was not performed in
the one episode for which cefuroxime was empirically ad-
ministered. Empirically administered amoxicillin/clavula-
nate and cefotaxime were non-susceptible to identified
pathogens in 16 (76.2 %) of the remaining 21 episodes.
Nevertheless, the non-susceptible amoxicillin/clavulanate
and cefotaxime had been administered until discharge
from hospital in all of the 16 episodes based on favourable
clinical responses. Amikacin was susceptible to identified
pathogens in all of the 18 episodes in which it was empiric-
ally administered. Empirical cefotaxime administered with-
out aminoglycosides was inappropriate in two (66.7 %) of
three episodes; however, fever disappeared 2 days after cef-
otaxime therapy, and second urine cultures became sterile
in both cases. Cefixime was administered for nine (42.9 %)
of the 21 episodes for which oral antibiotics were adminis-
tered after discharge from hospital, amoxicillin/clavulanate
for five (23.8 %), trimethoprim/sulfamethoxazole for four
(19.0 %), and cefditoren, cefpodoxime, and ciprofloxacin
for one (4.8 %) episode each. Although the identified
uropathogens were not susceptible to administered oral
antibiotics in 10 of the 11 episodes for which oral third-
generation cephalosporin was administered and in two of
Table 2 Empirical antibiotic therapy and therapeutic responses in children with urinary tract infection caused by E. coli or K.
pneumoniae
Factor Non-ESBL group ESBL group p-value
(n = 189) (n = 22)
Administered empirical antibiotics 0.814
With aminoglycoside
Third-generation cephalosporin + aminoglycoside 111 (58.7) 13 (59.1)
Aminopenicillin/β-lactamase inhibitor + aminoglycoside 34 (18.0) 4 (18.2)
Second-generation cephalosporin + aminoglycoside 4 (2.1) 1 (4.5)
Without aminoglycoside
Third-generation cephalosporin 25 (13.2) 3 (13.6)
Aminopenicillin/β-lactamase inhibitor 2 (1.1) 1 (4.5)
Second-generation cephalosporin 1 (0.5) 0 (0.0)
Others 10 (5.3) 0 (0.0)
No therapy 2 (1.1) 0 (0.0)
Appropriateness of empirical antibiotic therapya 182 (100.0) 20 (90.9) 0.011
Antibiotic duration (days)
Total 13.0 (12.0–14.0) 14.0 (13.0–16.0) 0.048
Intravenousb 6.0 (5.0–7.0) 6.0 (5.0–7.0) 0.742
Oralc 7.0 (7.0–9.0) 7.0 (6.0–10.5) 0.477
Aminoglycosidesd 6.0 (4.0–7.0) 6.0 (5.0–7.0) 0.170
Fever duration after antibiotic therapy (days)e 1.0 (0.0–2.0) 1.0 (0.0–1.3) 0.573
Response to empirical antibiotic therapy
Disappearance of fevere 172 (92.5) 20 (90.9) 0.680
Bacterial eradication on the urinef 174 (98.9) 21 (100.0) 1.000
Follow-up time of urine culture (days)f 2.0 (2.0–3.0) 2.0 (1.0–2.5) 0.611
Data are median (interquartile range) or no. (%) of cases
ESBL extended-spectrum β-lactamase
aThe appropriateness of empirical antibiotic therapy was determined in 204 children (182 in the non-ESBL group, 22 in the ESBL group)
bEleven children of the non-ESBL group, who did not received antibiotic therapy or received exclusively oral antibiotic therapy, were excluded
cSix children, who received exclusively intravenous antibiotic therapy, were excluded (Five in the non-ESBL group, One in the ESBL group)
dThe duration of aminoglycoside therapy was determined in 167 children (149 in the non-ESBL group, 18 in the ESBL group)
eThe accurate time of defervescence was not determined in three children in the non-ESBL group, who was lost to follow-up in the outpatient clinic
fMicrobiological response to first line antibiotics was determined in 197 children (176 in the non-ESBL group and 21 in the ESBL group) in whom repeated urine
cultures were performed before antibiotic change
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the five episodes for which oral amoxicillin/clavulanate was
administered, no re-emerging fever or urological symp-
toms were observed during oral antibiotic therapy.
Comparison of antibiotic susceptibility rates
The rates of susceptibility to empirically administered
BLs and BL/BLIs were significantly different between the
non-ESBL group (95.9 %, 162/169) and ESBL group
(23.8 %, 5/21, p < 0.001). However, 99.3 % (148/154) of
the episodes in the non-ESBL group and 100.0 % (18/18)
in the ESBL group were susceptible to empirically ad-
ministered aminoglycosides (p = 1.000).
Antibiotic susceptibility rates tended to be lower in the
ESBL group compared with the non-ESBL group (Table 3).
However, susceptibility rates to BL/BLIs (e.g. amoxicillin/
clavulanate and piperacillin/tazobactam) and to aminogly-
cosides (e.g. gentamicin, tobramycin, and amikacin) were
not significantly different between the two groups (Table 3).
No carbapenem-non-susceptible isolates were identified
during the study period.
Discussion
In the present study, therapeutic responses of febrile UTIs
to antibiotic therapy were compared between UTIs caused
by ESBL-producing strains and non-ESBL-producing
strains. Prescribing carbapenems has been restricted and
allowed only with the permission of the infectious disease
(ID) physicians in our hospital. Because attending physi-
cians discussed with ID physicians whether to administer
carbapenems or not to their patients, and ID physicians
decide based on the patient’s response to empirically ad-
ministered antibiotics, no children received carbapenems
in our study. There were no significant differences in the
clinical and microbiological responses of febrile UTIs to
non-carbapenem antibiotic therapy between the ESBL and
Table 3 Comparison of antibiotic susceptibility rates between the non-ESBL and ESBL groups
Antibiotics Non-ESBL group ESBL group p-value
(n = 189) (n = 22)
Penicillins
Ampicillin 44/131 (33.6) 0/18 (0.0) 0.003
Piperacillin 40/103 (38.8) 0/11 (0.0) 0.008
Cephalosporins
Cefoxitin 127/130 (97.7) 16/18 (88.9) 0.112
Cefotaxime 142/144 (98.6) 2/19 (10.5) <0.001
Caftazidime 185/189 (97.9) 10/22 (45.5) <0.001
Cefepime 186/189 (98.4) 10/22 (45.5) <0.001
β-lactam/β-latamase inhibitor combinations
Amoxicillin/clavulanate 107/131 (81.7) 12/18 (66.7) 0.205
Piperacillin/tazobactam 177/187 (94.7) 18/21 (85.7) 0.131
Carbapenems
Imipenem 189/189 (100.0) 22/22 (100.0) NA
Meropenem 189/189 (100.0) 22/22 (100.0) NA
Aminoglycosides
Gentamicin 158/188 (84.0) 16/22 (72.7) 0.228
Tobramycin 87/102 (85.3) 9/11 (81.8) 0.670
Amikacin 188/189 (99.5) 22/22 (100.0) 1.000
Isepamicin 58/58 (100.0) 4/4 (100.0) NA
Fluoroquinolones
Ciprofloxacin 128/145 (88.3) 8/15 (53.3) 0.002
Levofloxacin 42/44 (95.5) 5/7 (71.4) 0.086
Others
Trimethoprim/sulfamethoxazole 137/188 (72.9) 13/22 (59.1) 0.176
Colistin 58/58 (100.0) 4/4 (100.0) NA
Minocycline 47/58 (81.0) 4/4 (100.0) 1.000
Data are no. (%) of cases
ESBL extended-spectrum β-lactamase; NA not available
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non-ESBL groups. There was also no significant difference
in the frequency of APN or VUR between the two groups.
ESBLs are resistant to aminopenicillins and ureidopeni-
cillins as well as extended-spectrum β-lactam agents;
ESBLs also usually present resistance to other classes of
antibiotics, such as quinolones and trimethoprim/sulfa-
methoxazole [8, 13, 14]. Therefore, the broadest-spectrum
antibiotic agents, carbapenems, are recommended to treat
infections caused by ESBL-producing bacteria [7, 8]. Risk
factors for UTIs due to ESBL-producing strains in chil-
dren, including being less than 1 year old, having a recent
history of hospitalisation and antibiotic therapy with BLs,
the presence of underlying disease, and K. pneumoniae
infection, have been reported [1, 4–6, 15, 16]. Given that
carbapenem use should be restricted and most cases of
UTIs are not life-threatening, previous studies have fo-
cused on non-carbapenem antibiotics in UTIs due to
ESBL-producing strains [11, 12, 17–19]. However, few
studies have examined the therapeutic efficacy of non-
carbapenem antibiotics in childhood UTIs caused by
ESBL-producing strains [11, 12]. Cephamycins, which are
stable against ESBL, as well as fosfomycin and nitrofuran-
toin showed therapeutic effects for UTIs caused by ESBL-
producing strains [18, 20, 21]. However, data concerning
their efficacy and safety in children were insufficient for
these antibiotics. In addition, cephamycin therapy tends to
provoke inducible resistance to itself and occasionally to
carbapenems; therefore, cephamycin monotherapy for in-
fections due to ESBL-producing strains has not been ac-
cepted [7, 22].
In the present study, clinical and microbiological re-
sponses to non-carbapenem antibiotic therapy were not
significantly different between the ESBL and non-ESBL
groups, even though inappropriate empirical antibiotics
were administered in significantly more episodes in the
ESBL group than in the non-ESBL group. Previous studies
reported favourable outcomes of cephalosporin therapy in
UTIs caused by ESBL-producing strains despite the weak-
ness of cephalosporins against ESBL. This phenomenon
may have been due to higher antibiotic concentrations in
urine compared with serum [1, 12, 19]. Cefotaxime mono-
therapy in the ESBL group helped achieve defervescence
and urinary sterilisation in the present study, but there
were only two such cases. Although 50.0 % of the ESBL
group received third-generation oral cephalosporins after
discharge from hospital and there was no re-emergence of
fever or urological symptoms during oral antibiotic therapy,
most children of the ESBL group had received a median
of 6.0 days of aminoglycoside therapy during their hos-
pitalisation. Prolonged antibiotic effect of aminoglyco-
sides should be considered. In addition, no controlled
studies on the clinical efficacy of third-generation ceph-
alosporins in UTIs caused by ESBL-producing strains
have been conducted and the use of third-generation
cephalosporins is significantly associated with the develop-
ment of ESBL-producing strains [13, 16, 23]. Furthermore,
a recent study reported that ceftriaxone therapy in murine
pyelonephritis caused by ESBL-producing E. coli reduced
the renal bacterial burden but did not alter renal inflam-
mation [24]. This suggests that in vivo clinical efficacy and
long-term outcomes of third-generation cephalosporin
therapy in UTIs due to ESBL-producing strains should be
further evaluated.
Because clavulanate, a BLI, can inhibit ESBL activity,
BL/BLIs were considered an alternative to carbapenems in
treating infections due to ESBL-producing strains [25, 26].
In the present study, the susceptibility rates to amoxicil-
lin/clavulanate and piperacillin/tazobactam in the ESBL
group (66.7 % and 85.7 %, respectively) were higher than
those to cefotaxime, ceftazidime, and cefepime. In the
present study, aminoglycosides were empirically adminis-
tered for 79.1 % of the total episodes and 81.8 % of
episodes in the ESBL group. Only 23.8 % of the ESBL-
producing isolates in the present study were susceptible to
empirically administered BLs and BL/BLIs; however, all of
the ESBL-producing isolates were susceptible to empiric-
ally administered aminoglycosides. Therefore, empirically
administered aminoglycosides in the ESBL group may
have contributed to the non-significant findings in the
clinical and microbiological responses between the ESBL
and non-ESBL groups. Park et al. reported on the clinical
and microbiological effects of aminoglycosides in adults
and children with UTIs caused by ESBL-producing strains
[17], and the efficacy of aminoglycoside combination ther-
apy has also been demonstrated in bacteraemia caused by
ESBL-producing strains [27]. In the present study, tobra-
mycin and gentamicin, which have been used for several
decades, were susceptible against > 70 % of the ESBL-
producing isolates, and amikacin and isepamicin were
susceptible against all of the identified ESBL-producing
isolates. Therefore, empirical antibiotics for children pre-
sumably having UTIs should include aminoglycosides
considering that UTIs caused by ESBL-producing strains
have been increasing. Considering the possibility of having
reactive pyuria due to a bacterial infection other than a
UTI and urosepsis in febrile children with abnormal urin-
alysis and urinary microscopic examination results, empir-
ical administration of BLs or BL/BLIs in combination with
aminoglycosides and adjustment of antibiotics based on
the results of urine culture and antibiotic susceptibility of
the identified pathogens seem to be more reasonable than
empirical aminoglycoside monotherapy.
Given the retrospective nature of the present study, the
long-term outcomes of UTIs caused by ESBL-producing
strains could not be determined. Because we could not
control the administered antibiotics and none received
carbapenem therapy, treatment outcomes between carba-
penems and non-carbapenems could not be compared.
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Risk factors for UTIs due to ESBL-producing strains could
not be appropriately evaluated in the present study because
of the small number of cases in the ESBL group. Although
therapeutic effect of non-carbapenems in UTIs due to
ESBL-producing strains may change as the number of
these cases is increasing, other recent studies also showed
a favourable therapeutic effect of non-carbapenems in
UTIs caused by ESBL-producing strains [11, 12, 17–21].
However, further studies including a large number of cases
should be necessary to exactly define the effectiveness of
non-carbapenems in UTIs due to ESBL-producing strains.
The frequencies of APN and VUR may be inaccurate be-
cause the DMSA scan and VCUG were not performed uni-
versally, but in accordance with the attending physicians’
decisions. In addition, UTIs may be over-diagnosed be-
cause most urine samples in the present study were col-
lected using a urine bag. However, the present study
examined the data from febrile children with abnormal re-
sults on urine dipstick tests or flow cytometric analyses in
addition to positive urine cultures. APN based on the re-
sults of a DMSA scan was diagnosed in 80.4 % of the total
211 episodes. This rate is higher than rates reported in pre-
vious studies [2, 12]; therefore, the number of over-
diagnosed UTI episodes in the present study might be
small. Furthermore, although childhood UTIs need anti-
biotic therapy for 7 to 14 days [28], aminoglycosides can
cause treatment duration-related nephrotoxicity and oto-
toxicity [29]. Although definite nephrotoxicity was not
observed in the present study, ototoxicity was not evalu-
ated and serum creatinine levels were not repeatedly tested
during aminoglycoside therapy in half of the episodes.
Therefore, further studies determining the appropriate dur-
ation of aminoglycoside therapy, which guarantees both ef-
ficacy and safety should be performed. In the ESBL group,
rates of susceptibility to oral amoxicillin/clavulanate and
trimethoprim/sulfamethoxazole were 66.7 % and 59.1 %,
respectively, while 81.8 % (18/22) of ESBL-producing iso-
lates were susceptible to at least one of these two antibi-
otics. Therefore, the selection of oral antibiotics for UTIs
due to ESBL-producing strains should also be further
evaluated.
Conclusions
Childhood UTIs caused by ESBL-producing E. coli or K.
pneumoniae exhibited no significant difference in the clin-
ical and microbiological responses to non-carbapenem
antibiotic therapy compared with UTIs caused by non-
ESBL producing-strains. Empirical aminoglycoside therapy
may be responsible for these results. Aminoglycosides can
be an alternative to carbapenems in UTIs caused by
ESBL-producing strains; however, further studies regard-
ing oral antibiotic selection as well as the appropriate dur-
ation of intravenous aminoglycoside therapy are needed.
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